Prexigebersen - Bio-Path Holdings

Drug Profile

Prexigebersen - Bio-Path Holdings

Alternative Names: BP 100-1-01; BP-100-1.01; BP-1001; L-Grb-2; L-Grb-2 antisense; Liposomal Grb2 antisense oligonucleotide

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antisense oligonucleotides; Nucleotides
  • Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors; GRB2 adaptor protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Chronic myeloid leukaemia
  • Preclinical Colorectal cancer; Head and neck cancer; Lymphoma; Thyroid cancer
  • No development reported Breast cancer; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia in USA (IV, Injection)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in USA (IV, Injection)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top